Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study
Journal of Pediatric Gastroenterology and Nutrition · 2025-01 · 80 (1) · 113-123
DOI: 10.1002/jpn3.12384 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 16.10.2024. Verfasst von Soleynne Rébus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Crohn Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
Vedolizumab and ustekinumab are effective in inducing and maintaining corticosteroid‐free clinical remission (CFR) in adult patients with inflammatory bowel disease (IBD). This study describes the efficacy and safety of vedolizumab and ustekinumab in pediatric IBD.
Methods
All patients ≤18 years of age with Crohn's disease (CD) or ulcerative colitis (UC) treated with vedolizumab or ustekinumab in three centers in Northern France were followed retrospectively. The primary outcome was CFR at Week 14 (W14).
Results
Twenty‐five patients (9 CD, 16 UC) and 33 patients (28 CD, 5 UC) were started on vedolizumab and ustekinumab respectively between 2016 and 2021. All were previously treated with antitumor necrosis factor (TNF). The median time from diagnosis to treatment initiation was 21.0 (12.0–44.0) and 42.0 (22.0–73.5) months for vedolizumab and ustekinumab, respectively. Among vedolizumab‐treated patients, 36% were in CFR at W14, including 22% in CD and 44% in UC. At W52, 56% were in CFR, including 33% in CD and 69% in UC. Among ustekinumab‐treated patients, 49% were in CFR at W14, including 54% in CD and 20% in UC. At W52, 55% were in CFR, including 57% in CD and 40% in UC. There was a significant increase in median growth velocity between W0 and W52 of +2 SD in vedolizumab‐treated patients ( p = 0.0002). Four adverse events were reported during vedolizumab treatment, none for ustekinumab‐treated patients.
Conclusions
Vedolizumab and ustekinumab appear to be effective in inducing and maintaining CFR in pediatric‐onset IBD. Randomized controlled trials are needed to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, CHU Lille, Lille, France.
- Department of Pediatrics, Amiens-Picardie University Medical Center, Amiens, France.
- Medical Pediatrics Department, Caen Normandie UHC, Caen, France.
- Caen Univ., Inserm UMR 1073 ADEN, Rouen, France.
- Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
ORCID-Profile: Soleynne Rébus
Förderung
- None
Zitieren
APA
Rébus, S., Coopman, S., Djeddi, D., Vanrenterghem, A., Dupont, C., Lacotte, E., & Ley, D. (2025). Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study. Journal of Pediatric Gastroenterology and Nutrition, 80(1), 113-123. https://doi.org/10.1002/jpn3.12384
Vancouver
Rébus S, Coopman S, Djeddi D, Vanrenterghem A, Dupont C, Lacotte E, et al. Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study. Journal of Pediatric Gastroenterology and Nutrition. 2025;80(1):113-123. doi:10.1002/jpn3.12384
BibTeX
@article{Rbus2025,
author = {Rébus, Soleynne and Coopman, Stéphanie and Djeddi, Djamal and Vanrenterghem, Audrey and Dupont, Claire and Lacotte, Edouard and Ley, Delphine},
title = {Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
volume = {80},
number = {1},
pages = {113--123},
doi = {10.1002/jpn3.12384}
}
EUVIMED